AMENDMENT TO ASSET PURCHASE AGREEMENTAsset Purchase Agreement • September 7th, 2012 • Neogenix Oncology Inc • In vitro & in vivo diagnostic substances
THIS AMENDMENT TO ASSET PURCHASE AGREEMENT (this "Amendment") is entered into as of this 31st day of August 2012 by and between Precision Biologics, Inc., a Delaware corporation (“Purchaser”) and Neogenix Oncology, Inc., a Maryland corporation (“Seller”) and amends the Asset Purchase Agreement dated July 23, 2012 by and between Purchaser and Seller (the "Original Purchase Agreement", and as so amended, the "Purchase Agreement"). Terms defined in the Original Purchase Agreement and not otherwise defined herein are used herein as defined in the Original Purchase Agreement.
